M2 PHARMA-September 4, 2019-Sandoz announces global commercialisation deal for multiple sclerosis biosimilar
M2 EQUITYBITES-September 4, 2019-Sandoz announces global commercialisation deal for multiple sclerosis biosimilar
Global Banking News-September 3, 2019-Polpharma Biologics signs global commercialisation agreement for biosimilar
Natalizumab for MS
Fact.MR has announced the addition of the "Pegfilgrastim Biosimilar
Market Forecast, Trend Analysis & Competition Tracking - Global Review 2018 to 2028"report to their offering.
Coherus BioSciences is a leading biosimilar
company that develops and commercializes high-quality therapeutics for major regulated markets.
As prescription drug costs continue to increase, biosimilar
medicines represent hope for patients seeking access to more affordable treatment.
M2 PRESSWIRE-July 29, 2019-: Biosimilar
Market Trends Report 2019: EU Guidelines, US Guidelines, Interchangeability, Patent and Patent Dance Issues
Amgen (AMGN) and Allergan (AGN) announced that Mvasi, a biosimilar
to Avastin, and Kanjinti, a biosimilar
to Herceptin, are now available in the United States.
(Alliance News) - US biopharmaceutical firm Amgen Inc said Thursday two of its biosimilar
cancer treatments are now available in the US.
* Biogen's three biosimilar
treatments--BENEPALI[TM] (etanercept), FLIXABI[TM] (infliximab) and IMRALDI[TM] (adalimumab)--are estimated to save the European healthcare system 1.8 billion euros in 2019
Effective October 10, 2018, agreements between brand and biosimilar
drug manufacturers regarding the manufacture, marketing, and sale of biosimilar
versions of reference drug products must be filed with the FTC and the DOJ.
The agreement covers multiple biosimilar
candidates from Samsung Bioepis, including third-wave biosimilar
candidates SB11 and SB12, which reference Lucentis (ranibizumab) and Soliris (eculizumab), respectively, as well as SB3, a biosimilar
candidate referencing Herceptin 3 (trastuzumab).